Definitive Contract 75N91025C00001
Award Date
12/2/24
Potential Completion Date
12/2/29
Potential Value
$35M
Federal Agency
National Cancer Institute
Awardee
Azenta US Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South Plainfield, NJ 07080, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to Azenta US Inc., doing business as Brooks Life Sciences Inc., for DNA whole exome sequencing services to support new studies under the NCI's Childhood Cancer Data Initiative. The period of performance is from July 27, 2020 to July 26, 2023, with a total ceiling value of $479,145. This contract is part of the NCI Genomic Characterization Centers contract vehicle, a larger indefinite...
The National Institute of Environmental Health Sciences (NIEHS) awarded a $1,127,150.00 firm fixed-price purchase order to Azenta US Inc., doing business as Brooks Life Sciences Inc., for NextGen sequencing services. The contract is for up to 250 samples per year from various tissue, cell culture, and liquid biopsy sources on Illumina platforms. This requirement was initially solicited without a set-aside designation. The contract has an ultimate completion date of July 13, 2026. Azenta US...
This federal contract award, valued at $27,664,149.00, was made by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the Childhood Cancer Data Initiative: Clinical Trial Specimen Molecular Characterization (CTSMC) Program, which involves delivering a comprehensive range of biomedical research and facilities support services to the NCI. This includes services such as facilities operations and maintenance, research and...
This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract, valued at $78,651,080, is a cost-plus-fixed-fee delivery order to support the NCI's clinical and research data sharing initiatives. The contract has no set-aside designation. Under this contract, Leidos Biomedical Research Inc. will develop a data federation...
This is a firm fixed-price purchase order contract awarded by the National Institute of Diabetes and Digestive and Kidney Diseases, a civilian agency within the Department of Health and Human Services, to Azenta US Inc. (doing business as Brooks Life Sciences Inc.) on November 1, 2022. The contract has a ceiling value of $10,237.96 and a period of performance ending on July 18, 2025. The contract was awarded without any set-aside designation. Azenta US Inc. is a subsidiary of the parent...
This is a delivery order contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to the Research Institute at Nationwide Children's Hospital, a non-profit organization. The $15,747,919.64 contract is for the Center for Cancer Genomics (CCG) Biospecimen Core Resource (BCR) and has a firm fixed price pricing structure with an ultimate completion date of August 24, 2022. No set-aside was used. The contract involves providing research services,...
The National Cancer Institute awarded Nzumbe Inc. a $355,000 firm fixed price definitive contract under the Small Business Innovation Research Concept Award program. This program seeks proposals from small businesses for innovative concepts to advance pediatric and rare cancer therapies, diagnostics, or preventatives. Specifically, Nzumbe will demonstrate technical feasibility and proof-of-concept for a highly innovative pediatric or rare cancer idea through preliminary experiments, while also...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Azenta US Inc., doing business as Brooks Life Sciences Inc. The contract, valued at $12,513.00, is for genomic DNA re-extraction from frozen stool samples, with an ultimate completion date of May 10, 2024. The contract has no set-aside designation. Azenta is a subsidiary of the parent company Azenta, Inc., which is a...
The National Cancer Institute (NCI) awarded a Firm Fixed Price Definitive Contract to Navipoint Genomics LLC, a minority-owned small business, under the SBIR Program Phase II. The contract, valued at $1,679,321.00, is for the development of cloud-based software to support the Cancer Research Data Commons project. This project aims to enable precision oncology by facilitating collaboration in the cloud. The contract has a completion date of May 31, 2025 and is set aside for small businesses.